Recently diagnosed with HIV? Click here

Vaccine research worth supporting

Positive Living article • Adrian Ogier • 26 November 2009
Defeating HIV

Two ‘broadly neutralising’ antibodies have recently been isolated from a sub­Saharan African donor.

Apparently, these particular antibodies not only target multiple strains of HIV (i.e., they are broadly neutralising) but they also bind tightly to the virusA small infective organism which is incapable of reproducing outside a host cell. and work at minute levels compared to previously discovered neutralising antibodies.

They have also revealed a more vulnerable and easier­to­reach spot on the virus that no previously known antibody targets.

The unusual features of these two antibodies provide exciting new leads for the design of HIV vaccines. Potentially, they could stimulate the body to make potent antibodies active against a broad range of strains of HIV.

Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

From Positive Living

This article was first published in the December 2009 issue of Positive Living.

While the content of this was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update